The pursuit of developing nanomedicines capable of extrahepatic delivery has driven rapid growth in new nanomaterials and nanoparticle formulations.1,2,3,4,5 Thus, developing a rational and effective strategy to rapidly screen and down-select these newly developed formulations for their overall delivery performance in vitro and in vivo could be beneficial to the nanomedicine field. In this issue of Molecular Therapy Nucleic Acids, Song et al. developed a workflow using the ionizable lipid C14120 to generate a library of lipid nanoparticles (LNPs) with diverse formulation ratios.
Fung et al. (Mon,) studied this question.